Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 15/20 | 0.84 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16659469 | 0.91 | FGFR1 (1.00) | FGFR1FGFR3FGFR4FGFR2 | |
| SCHEMBL581714 | 0.88 | FGFR1 (0.74) | FGFR1FGFR3CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL16659450 | 0.84 | FGFR1 (1.00) | FGFR1FGFR3FGFR4FGFR2 | |
| SCHEMBL16659604 | 0.82 | FGFR1 (0.83) | FGFR1FGFR3FGFR4FGFR2 | |
| SCHEMBL22171984 | 0.82 | FGFR4 (0.83) | FGFR1FGFR3CYP3A4CYP2C19FGFR4 | |
| SCHEMBL19250256 | 0.81 | FGFR1 (0.84) | FGFR1FGFR3CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL374601 | 0.81 | FGFR3 (0.80) | FGFR1FGFR3CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL22173856 | 0.80 | FGFR1 (0.84) | FGFR1FGFR3FGFR4FGFR2 | |
| SCHEMBL16659489 | 0.79 | FGFR1 (1.00) | FGFR1FGFR3FGFR4FGFR2 | |
| SCHEMBL373990 | 0.79 | FGFR3 (0.65) | FGFR1FGFR3CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR1 2/4885FGFR3 3/4885CYP3A4 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.